Summit Therapeutics (SMMT) EPS (Diluted) Growth (1y) (2018 - 2024)
Analysis
Summit Therapeutics (SMMT) EPS (Diluted) Growth (1y) (2018 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 89.89% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 144.25% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 315.14% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -11.18% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 96.41% |
| 10 | Summit Therapeutics | 13.67 Bn | 12.98 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -56.29% |
| Sep 30, 2024 | -185.04% |
| Jun 30, 2024 | -291.37% |
| Mar 31, 2024 | 95.43% |
| Dec 31, 2023 | 44.34% |
| Sep 30, 2023 | 74.24% |
| Jun 30, 2023 | 82.23% |
| Mar 31, 2023 | -527.54% |
| Dec 31, 2022 | 64.26% |
| Sep 30, 2022 | 43.31% |
| Jun 30, 2022 | 52.71% |
| Mar 31, 2022 | -7.00% |
| Dec 31, 2021 | -50.84% |
| Sep 30, 2021 | 23.79% |
| Jun 30, 2021 | -18.52% |
| Mar 31, 2021 | -124.28% |
| Dec 31, 2020 | 14.52% |
| Sep 30, 2020 | -32.86% |
| Mar 31, 2020 | 76.66% |
| Oct 31, 2019 | -212.85% |